Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure

Experimental Physiology

Volumn 95, Issue 1, 2010, Pages 19-25

  Felder, Robert B ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CATECHOLAMINE; CORTICOTROPIN RELEASING FACTOR; CYCLOOXYGENASE 2; CYTOKINE; DEOXYCORTICOSTERONE ACETATE; EPLERENONE; ETANERCEPT; GLUCOCORTICOID; INTERLEUKIN 1BETA; KETOROLAC; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NORADRENALIN; OXPRENOATE POTASSIUM; PENTOXIFYLLINE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN P42; PROTEIN P44; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ASCITES; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN CORTEX; BRAIN MICROCIRCULATION; CEREBROSPINAL FLUID LEVEL; CONFERENCE PAPER; CONTINUOUS INFUSION; CYTOKINE RELEASE; ENZYME ACTIVITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HYPERTENSION; HYPOTHALAMUS; INFLAMMATION; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; NERVE CONDUCTION; NONHUMAN; PLEURA EFFUSION; PROSTAGLANDIN SYNTHESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; SIGNAL TRANSDUCTION; SYMPATHETIC TONE; SYSTOLIC HEART FAILURE; THALAMUS MIDLINE NUCLEUS; URINE VOLUME;

EID: 74049150347     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2008.045948     Document Type: Conference Paper

References (52)

1. Callera GE, Montezano AC, Yogi A, Tostes RC, He Y, Schiffrin EL Touyz RM (2005). C-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 46, 1032 1038.
2. Chrousos GP (2000). The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann N Y Acad Sci 917, 38 67.
3. Connell JM Davies E (2005). The new biology of aldosterone. J Endocrinol 186, 1 20.
4. De Nicola AF, Grillo C Gonzalez S (1992). Physiological, biochemical and molecular mechanisms of salt appetite control by mineralocorticoid action in brain. Braz J Med Biol Res 25, 1153 1162.
5. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG Mann DL (2001). Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 103, 2055 2059. (Pubitemid 32373007)
6. Dibbs Z, Kurrelmeyer K, Kalra D, Seta Y, Wang F, Bozkurt B, Baumgarten G, Sivasubramanian N Mann DL (1999). Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc Assoc Am Physicians 111, 423 428.
7. Dunn AJ (2000). Cytokine activation of the HPA axis. Ann N Y Acad Sci 917, 608 617.
8. Ericsson A, Arias C Sawchenko PE (1997). Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J Neurosci 17, 7166 7179.
9. Ericsson A, Kovacs KJ Sawchenko PE (1994). A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J Neurosci 14, 897 913.
10. 2. Brain Res 231, 335 342.
11. Francis J, Beltz T, Johnson AK Felder RB (2003a). Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-α in normal rats. Am J Physiol Regul Integr Comp Physiol 285, R1402 R1409.
12. Francis J, Chu Y, Johnson AK, Weiss RM Felder RB (2004a). Acute myocardial infarction induces hypothalamic cytokine synthesis. Am J Physiol Heart Circ Physiol 286, H2264 H2271.
13. Francis J, Wei S-G, Weiss RM Felder RB (2004b). Brain angiotensin-converting enzyme activity and autonomic regulation in heart failure. Am J Physiol Heart Circ Physiol 287, H2138 H2146.
14. Francis J, Weiss RM, Johnson AK Felder RB (2003b). Central mineralocorticoid receptor blockade decreases plasma TNF-α after coronary artery ligation in rats. Am J Physiol Regul Integr Comp Physiol 284, R328 R335.
15. Francis J, Weiss RM, Wei S-G, Johnson AK, Beltz TG, Zimmerman K Felder RB (2001a). Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 281, H2241 H2251.
16. Francis J, Weiss RM, Wei S-G, Johnson AK Felder RB (2001b). Progression of heart failure after myocardial infarction in the rat. Am J Physiol Regul Integr Comp Physiol 281, R1734 R1745.
17. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG Zucker IH (2004). Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res 95, 937 944.
18. Gómez-Sánchez EP (1997). Central hypertensive effects of aldosterone. Front Neuroendocrinol 18, 440 462.
19. Gomez-Sanchez EP, Ahmad N, Romero DG Gomez-Sanchez CE (2005). Is aldosterone synthesized within the rat brain? Am J Physiol Endocrinol Metab 288, E342 E346.
20. Gómez-Sánchez EP, Fort CM Gómez-Sánchez CE (1990). Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol Endocrinol Metab 258, E482 E484.
21. Gómez-Sánchez EP, Zhou M Gomez-Sanchez CE (1996). Mineralocorticoids, salt and high blood pressure. Steroids 61, 184 188.
22. Grossmann C Gekle M (2008). Nongenotropic aldosterone effects and the EGFR: interaction and biological relevance. Steroids 73, 973 978.
23. Guggilam A, Haque M, Kerut EK, McIlwain E, Lucchesi P, Seghal I Francis J (2007). TNF-α blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats. Am J Physiol Heart Circ Physiol 293, H599 H609.
24. Guggilam A, Patel KP, Haque M, Ebenezer PJ, Kapusta DR Francis J (2008). Cytokine blockade attenuates sympathoexcitation in heart failure: cross-talk between nNOS, AT-1R and cytokines in the hypothalamic paraventricular nucleus. Eur J Heart Fail 10, 625 634
25. 2. J Physiol 288, 159 169.
26. Huang BS, White RA, Ahmad M, Tan J, Jeng AY Leenen FHH (2009). Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction. Cardiovasc Res 81, 574 581.
27. Kang Y-M, Zhang Z-H, Johnson RF, Yu Y, Beltz T, Johnson AK, Weiss RM Felder RB (2006). Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circ Res 99, 758 766.
28. Kang Y-M, Zhang Z-H, Xue B, Weiss RM Felder RB (2008). Inhibition of brain proinflammatory cytokine synthesis reduces hypothalamic excitation in rats with ischemia-induced heart failure. Am J Physiol Heart Circ Physiol 295, H227 H236.
29. Kjaer A Hesse B (2001). Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin Physiol 21, 661 672. (Pubitemid 33120896)
30. Lal A, Veinot JP Leenen FH (2004). Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovasc Res 64, 437 447.
31. Leenen FH, Skarda V, Yuan B White R (1999). Changes in cardiac ANG II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors. Am J Physiol Heart Circ Physiol 276, H317 H325.
32. Liu D, Gao L, Roy SK, Cornish KG Zucker IH (2006). Neuronal angiotensin II type 1 receptor upregulation in heart failure: activation of activator protein 1 and Jun N-terminal kinase. Circ Res 99, 1004 1011.
33. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J Hong Y, Writing Group Members for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2009). Heart Disease and Stroke Statistics - 2009 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, e21 e181.
34. McKinley MJ, McAllen RM, Pennington GL, Smardencas A, Weisinger RS Oldfield BJ (1996). Physiological actions of angiotensin II mediated by AT1 and AT2 receptors in the brain. Clin Exp Pharmacol Physiol Suppl 3, S99 S104.
35. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J Wittes J (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators see comments N Engl J Med 341, 709 717.
36. Rahmouni K, Barthelmebs M, Grima M, Imbs JL De Jong W (1999). Brain mineralocorticoid receptor control of blood pressure and kidney function in normotensive rats. Hypertension 33, 1201 1206.
37. Rivest S, Lacroix S, Vallieres L, Nadeau S, Zhang J Laflamme N (2000). How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 223, 22 38.
38. Rousseau MF, Gurne O, Duprez D, Van Mieghem W, Robert A, Ahn S, Galanti L Ketelslegers J-M Belgian RALES Investigators (2002). Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 40, 1596 1601.
39. Schiltz JC Sawchenko PE (2002). Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J Neurosci 22, 5606 5618.
40. Schiltz JC Sawchenko PE (2003). Signaling the brain in systemic inflammation: the role of perivascular cells. Front Biosci 8, s1321 s1329.
41. 1 receptor and ACE densities after myocardial infarct in rats. Am J Physiol Heart Circ Physiol 286, H1665 H1671.
42. Torres M Forman HJ (2003). Redox signaling and the MAP kinase pathways. Biofactors 17, 287 296.
43. Turnbull AV Rivier CL (1999). Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 79, 1 71.
44. Weber KT, Sun Y, Campbell SE, Slight SH, Ganjam VK, Griffing GT, Swinfard RW Diaz-Arias AA (1995). Chronic mineralocorticoid excess and cardiovascular remodeling. Steroids 60, 125 132.
45. 1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol Heart Circ Physiol 296, H1425 H1433.
46. Wei S-G, Yu Y, Zhang Z-H, Weiss RM Felder RB (2008). Angiotensin II-triggered p44/42 mitogen-activated protein kinase mediates sympathetic excitation in heart failure rats. Hypertension 52, 342 350.
47. Yu Y, Kang YM, Zhang Z-H, Wei S-G, Chu Y, Weiss RM Felder RB (2007). Increased cyclooxygenase-2 expression in hypothalamic paraventricular nucleus in rats with heart failure: role of nuclear factor κB. Hypertension 49, 511 518.
48. Yu Y, Wei S-G, Zhang Z-H, Gomez-Sanchez E, Weiss RM Felder RB (2008). Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension 51, 727 733. (Pubitemid 351301527)
49. Zhang Z-H, Wei S-G, Francis J Felder RB (2003). Cardiovascular and renal sympathetic activation by blood-borne TNF-α in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 284, R916 R927.
50. Zhang Z-H, Yu Y, Kang Y-M, Wei S-G Felder RB (2008). Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 294, H1067 H1074.
51. Zhang Z-H, Yu Y, Wei S-G Felder RB (2009). Aldosterone induces sympatho-excitation via brain mitogen-activated protein kinase signaling pathways in rat. FASEB J 23, 610.3.
52. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR Davisson RL (2002). Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 91, 1038 1045.